Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants
Bioequivalence Study of the Fixed Dose Combination of 2.5 mg Saxagliptin and 500 mg Metformin Tablet Relative to a 2.5 mg Saxagliptin (Onglyza) Tablet and a 500 mg Metformin (Glucophage Marketed in Canada by Sanofi-Aventis) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Texas
-
Austin, Texas, Forenede Stater, 78744
- PPD Development, LP
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Men and women, aged 18 to 55 years, inclusive
- Healthy participants as determined by a lack of clinically significant deviation from normal in medical history, physical examination, electrocardiograms, and clinical laboratory determinations
- Body Mass Index of 18 to 32 kg/m^2, inclusive
Exclusion Criteria:
- Any significant acute or chronic medical illness
- Current or recent (within 3 months) gastrointestinal disease
- Any major surgery within 4 weeks of study drug administration
- History of allergy to DPP-4 inhibitors or related compounds
- History of allergy or intolerance to metformin or other similar acting agents
- Previous exposure to saxagliptin
- Exposure to metformin within 3 months pervious to study drug administration
- Estimated creatinine clearance of <80 mL/min using the Cockcroft Gault formula
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Andet: Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)
Single oral doses of saxagliptin, 2.5 mg, and metformin, 500 mg, administered together as tablets in the fasted state
|
Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
Andre navne:
|
|
Andet: Saxagliptin, 2.5 mg/Metformin, 500 mg FDC (fasted state)
Single oral dose of a 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) tablet administered in the fasted state
|
Tablets, oral, 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC), once daily, 1 week
|
|
Andet: Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)
Single oral doses of saxagliptin, 2.5 mg, and metformin, 500 mg, administered together as tablets in the fed state
|
Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
Andre navne:
|
|
Andet: Saxagliptin, 2.5 mg/Metformin, 500 mg FDC (fed state)
Single oral dose of saxagliptin, 2.5 mg/metformin, 500 mg, FDC tablet administered in the fed state
|
Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin FDC, once daily, 1 week
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Observed Maximum Plasma Concentration (Cmax) of Saxagliptin, Tablets and Fixed-dose Combination (FDC), Administered to Participants in the Fasted and Fed States
Tidsramme: Days 1, 2, and 3 of Periods 1, 2, 3, and 4
|
Days 1, 2, and 3 of Periods 1, 2, 3, and 4
|
|
Observed Cmax of Metformin, Tablets and FDC, Administered to Participants in the Fasted and Fed States
Tidsramme: Days 1, 2, and 3 of Periods 1, 2, 3, and 4
|
Days 1, 2, and 3 of Periods 1, 2, 3, and 4
|
|
Terminal Half-life (t1/2) of Saxagliptin and Metformin, Tablets and FDC, Administered to Participants in the Fasted and Fed States
Tidsramme: Days 1, 2, and 3 of Periods 1, 2, 3, and 4
|
Days 1, 2, and 3 of Periods 1, 2, 3, and 4
|
|
Area Under the Plasma Concentration-time Curve From Time 0 to the Last Quantifiable Concentration (AUC[0-t]) for Saxagliptin, Tablets and FDC, Given in the Fasted and Fed States
Tidsramme: Days 1, 2, and 3 of Periods 1, 2, 3, and 4
|
Days 1, 2, and 3 of Periods 1, 2, 3, and 4
|
|
AUC[0-t] for Metformin, Tablets and FDC, Given in the Fasted and Fed States
Tidsramme: Days 1, 2, and 3 of Periods 1, 2, 3, and 4
|
Days 1, 2, and 3 of Periods 1, 2, 3, and 4
|
|
AUC From Time 0 Extrapolated to Infinity (AUC[0-inf]) for Saxagliptin, Tablets and FDC, Given in the Fasted and Fed States
Tidsramme: Days 1, 2, and 3 of Periods 1, 2, 3, and 4
|
Days 1, 2, and 3 of Periods 1, 2, 3, and 4
|
|
AUC[0-inf] for Metformin, Tablets and FDC, Administered in the Fasted and Fed States
Tidsramme: Days 1, 2, and 3 of Periods 1, 2, 3, and 4
|
Days 1, 2, and 3 of Periods 1, 2, 3, and 4
|
|
Time to Achieve the Observed Maximum Plasma Concentration (Tmax) for Saxagliptin and Metformin, Tablets and FDC, Administered to Participants in the Fasted and Fed States
Tidsramme: Days 1, 2, and 3 of Periods 1, 2, 3, and 4
|
Days 1, 2, and 3 of Periods 1, 2, 3, and 4
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants With Death as Outcome, Serious Adverse Events, and Adverse Events (AEs) Leading to Discontinuation
Tidsramme: Continuously over Days 1 to 3 of treatment Periods 1, 2, 3, and 4
|
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment.
An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
|
Continuously over Days 1 to 3 of treatment Periods 1, 2, 3, and 4
|
|
Number of Participants With Clinically Significant Abnormalities in Hematology, Serum Chemistry, and Urinalysis Laboratory Test Results
Tidsramme: At screening visit, at Day -1 of Periods 1 through 4, and at discharge
|
Clinically significant was determined by the investigator.
Hematology tests included hemoglobin, hematocrit, red blood cell count, total leukocyte count (including differential), and platelet count.
Serum chemistry tests included aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, lactate dehydrogenase, creatinine, blood urea nitrogen, uric acid, fasting glucose, total protein, albumin, sodium, potassium, chloride, calcium, phosphorus, and creatine kinase.
Urinalysis included protein, glucose, blood, leukocyte esterase, specific gravity, and pH.
|
At screening visit, at Day -1 of Periods 1 through 4, and at discharge
|
|
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Results
Tidsramme: At screening visit, Day -1 of Period 1, and at study discharge
|
Clinically significant was determined by the investigator.
ECGs were recorded after participants had been supine for at least 5 minutes.
|
At screening visit, Day -1 of Period 1, and at study discharge
|
|
Number of Participants With Clinically Significant Abnormalities in Body Temperature, Blood Pressure, or Heart Rate
Tidsramme: At screening visit, prior to dosing on Day 1 of Periods 1 through 4, and at study discharge.
|
Clinically significant was determined by the investigator.
Blood pressure and heart rate were measured after the participant had been seated quietly for at least 5 minutes.
|
At screening visit, prior to dosing on Day 1 of Periods 1 through 4, and at study discharge.
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Glukosemetabolismeforstyrrelser
- Metaboliske sygdomme
- Sygdomme i det endokrine system
- Diabetes mellitus
- Diabetes mellitus, type 2
- Hypoglykæmiske midler
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Enzymhæmmere
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Proteasehæmmere
- Inkretiner
- Dipeptidyl-Peptidase IV-hæmmere
- Metformin
- Saxagliptin
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CV181-118
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .